Reporter’s Notebook < Opinion < Article List

[Reporter's Notebook] The abandoned Hanmi-OCI merger shows the power of the small shareholders
Reporter’s Notebook Lee Han-soo 03.29 13:20
[Reporter's Notebook] Is lawmaker's claim that Celltrion's Covid-19 drug was a failure true?
Reporter’s Notebook Lee Han-soo 2023.10.12 13:06
[Reporter's Notebook] Korean companies bet on Cancer Moonshot but uncertainty looms
Reporter’s Notebook Lee Han-soo 2023.09.01 15:49
[Reporter's Notebook] GemVax & KAEL's 'miracle cure' for Alzheimer's disease needs scrutiny
Reporter’s Notebook Lee Han-soo 2023.07.19 11:34
[Reporter's Notebook] Is ‘special listing’ system hurting biotech industry?
Reporter’s Notebook Lee Han-soo 2023.04.13 17:28
[Reporter's notebook] Cheering for Lilly Korea’s bid
Reporter’s Notebook Kim Yun-mi 2023.03.09 15:32
Mundipharma Korea, a ‘good place to work,’ suspends employees refusing ERP
Reporter’s Notebook Jeong Min-jun 2023.03.07 15:26
[Reporter's Notebook] Lost are the government's bio-industry promotion policies for 2023
Reporter’s Notebook Kim Chan-hyuk 2023.01.31 16:16
Korean biopharma shouldn’t make promises if they can’t keep them
Reporter’s Notebook Lee Han-soo 2022.11.02 13:55
Global Bio Conference, not ‘global’ at all
Reporter’s Notebook Lee Han-soo 2022.09.08 14:43
[Reporter’s Notebook] Why does Janssen need a PR department – or an offshoot -- in Korea?
Reporter’s Notebook Lee Han-soo 2022.04.12 16:47
[Reporter’s Notebook] Rival candidates ‘politicize’ foreign residents’ health insurance issue
Reporter’s Notebook Lee Han-soo 2022.02.03 17:32
[Reporter's Notebook] USFK must follow quarantine rules
Reporter’s Notebook Lee Han-soo 2021.05.31 14:46
[Reporter's Notebook] Drugmakers introduce creative PR formats amid Covid-19
Reporter’s Notebook Lee Han-soo 2020.06.25 11:04
[Reporter's Notebook] Korean firms found something missing in ‘virtual’ ASCO 2020
Reporter’s Notebook Lee Han-soo 2020.06.08 16:45
[Reporter's Notebook] Korean biopharmaceuticals have long way to go before reaching foreigners
Reporter’s Notebook Lee Han-soo 2019.12.11 16:58
[Reporter's Notebook] Korean drugmakers should increase presence at global conventions
Reporter’s Notebook Lee Han-soo 2019.06.21 15:24
[Reporter’s Notebook]MFDS incapable of reviewing new drugs?
Reporter’s Notebook Lee Hye-seon 2019.04.29 16:09
[Reporter’s Notebook] Concerns over TB risk rise amid more use of TNF-α inhibitors
Reporter’s Notebook Kim Yun-mi 2019.03.29 17:10
[Reporter’s Notebook] Is Korean market unimportant for Samsung Bioepis?
Reporter’s Notebook Nam Doo-hyun 2018.08.16 14:18

상단영역

본문영역

Reporter’s Notebook 목록 ( 총 : 20 )

기사목록 보기 형태

[Reporter's Notebook] The abandoned Hanmi-OCI merger shows the power of the small shareholders

[Reporter's Notebook] Is lawmaker's claim that Celltrion's Covid-19 drug was a failure true?

[Reporter's Notebook] Korean companies bet on Cancer Moonshot but uncertainty looms

[Reporter's Notebook] GemVax & KAEL's 'miracle cure' for Alzheimer's disease needs scrutiny

[Reporter's Notebook] Is ‘special listing’ system hurting biotech industry?

[Reporter's notebook] Cheering for Lilly Korea’s bid

Mundipharma Korea, a ‘good place to work,’ suspends employees refusing ERP

[Reporter's Notebook] Lost are the government's bio-industry promotion policies for 2023

Korean biopharma shouldn’t make promises if they can’t keep them

Global Bio Conference, not ‘global’ at all

[Reporter’s Notebook] Why does Janssen need a PR department – or an offshoot -- in Korea?

[Reporter’s Notebook] Rival candidates ‘politicize’ foreign residents’ health insurance issue

[Reporter's Notebook] USFK must follow quarantine rules

[Reporter's Notebook] Drugmakers introduce creative PR formats amid Covid-19

[Reporter's Notebook] Korean firms found something missing in ‘virtual’ ASCO 2020

[Reporter's Notebook] Korean biopharmaceuticals have long way to go before reaching foreigners

[Reporter's Notebook] Korean drugmakers should increase presence at global conventions

[Reporter’s Notebook]MFDS incapable of reviewing new drugs?

[Reporter’s Notebook] Concerns over TB risk rise amid more use of TNF-α inhibitors

[Reporter’s Notebook] Is Korean market unimportant for Samsung Bioepis?